Latest news

DegenRx selected for GES 2019

Click to read the latest news

Where to meet us

AAIC2019, July 14-18, Los Angeles, USA

More info

DegenRx is a biotech company developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer’s and Parkinson’s disease. Using Adeno-Associated-Viral (AAV) vectors we deliver genes in the brain that initiate the local production of therapeutic antibodies.

Our ambition: by just a single administration we achieve a highly efficient treatment that lasts for years delivered at the target site without exposing the rest of the body.